CN103157062A - 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 - Google Patents
一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN103157062A CN103157062A CN2012104472638A CN201210447263A CN103157062A CN 103157062 A CN103157062 A CN 103157062A CN 2012104472638 A CN2012104472638 A CN 2012104472638A CN 201210447263 A CN201210447263 A CN 201210447263A CN 103157062 A CN103157062 A CN 103157062A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- radix
- hysteromyoma
- gynecological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 69
- 201000010099 disease Diseases 0.000 title claims abstract description 67
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title abstract description 14
- 201000010260 leiomyoma Diseases 0.000 title abstract 3
- 241000218176 Corydalis Species 0.000 claims abstract description 41
- 238000000605 extraction Methods 0.000 claims abstract description 25
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 23
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 238000004321 preservation Methods 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000003094 microcapsule Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- 238000011282 treatment Methods 0.000 claims description 54
- 210000000582 semen Anatomy 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 238000003756 stirring Methods 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000004615 ingredient Substances 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 30
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000600871 Euryale <brittle star> Species 0.000 claims description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 22
- 235000005903 Dioscorea Nutrition 0.000 claims description 20
- 241000234273 Dioscorea Species 0.000 claims description 20
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 18
- 208000025661 ovarian cyst Diseases 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 14
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 14
- 239000001569 carbon dioxide Substances 0.000 claims description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 13
- 230000006837 decompression Effects 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000019634 flavors Nutrition 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 13
- 238000004064 recycling Methods 0.000 claims description 13
- 239000002893 slag Substances 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- -1 adding 8~16 times Substances 0.000 claims description 12
- 238000013019 agitation Methods 0.000 claims description 11
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 5
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 4
- 206010008254 Cervical cyst Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 208000015994 miscarriage Diseases 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 208000000995 spontaneous abortion Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 241000521257 Hydrops Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 claims description 3
- 206010038351 renal abscess Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 240000000233 Melia azedarach Species 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000268590 Euryale ferox Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000009022 Smilax rotundifolia Species 0.000 abstract 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 95
- 210000004369 blood Anatomy 0.000 description 93
- 208000002193 Pain Diseases 0.000 description 32
- 230000036407 pain Effects 0.000 description 32
- 210000004185 liver Anatomy 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 22
- 210000001015 abdomen Anatomy 0.000 description 16
- 239000007789 gas Substances 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 210000005075 mammary gland Anatomy 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000004087 circulation Effects 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 8
- 230000005906 menstruation Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 208000019255 Menstrual disease Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- 206010019909 Hernia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000029312 Muscular tumor Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 4
- 229960000452 diethylstilbestrol Drugs 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008956 guizhi-fuling Substances 0.000 description 4
- 208000035861 hematochezia Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010006298 Breast pain Diseases 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 208000006662 Mastodynia Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000017561 flaccidity Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004914 menses Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001161070 Calomela Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010040102 Seroma Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 231100000536 menstrual disturbance Toxicity 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210447263.8A CN103157062B (zh) | 2012-11-09 | 2012-11-09 | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210447263.8A CN103157062B (zh) | 2012-11-09 | 2012-11-09 | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103157062A true CN103157062A (zh) | 2013-06-19 |
CN103157062B CN103157062B (zh) | 2015-03-18 |
Family
ID=48580927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210447263.8A Active CN103157062B (zh) | 2012-11-09 | 2012-11-09 | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103157062B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105311325A (zh) * | 2015-10-27 | 2016-02-10 | 李成艳 | 一种治疗子宫肌瘤的组合物栓剂及其制备方法 |
CN106177797A (zh) * | 2016-08-30 | 2016-12-07 | 佛山市弘泰药物研发有限公司 | 一种妇科炎症的中成药及其制备工艺 |
CN111265602A (zh) * | 2020-03-31 | 2020-06-12 | 江西普正制药股份有限公司 | 血平制剂在制备治疗子宫肌瘤药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820780A (zh) * | 2005-02-19 | 2006-08-23 | 李砚秋 | 妇炎康提取物的制备方法 |
CN101129916A (zh) * | 2007-08-21 | 2008-02-27 | 王军 | 当归元胡蜜丸 |
CN102652819A (zh) * | 2012-03-06 | 2012-09-05 | 深圳市国源药业有限公司 | 一种妇炎康分散片及其制备方法 |
-
2012
- 2012-11-09 CN CN201210447263.8A patent/CN103157062B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820780A (zh) * | 2005-02-19 | 2006-08-23 | 李砚秋 | 妇炎康提取物的制备方法 |
CN101129916A (zh) * | 2007-08-21 | 2008-02-27 | 王军 | 当归元胡蜜丸 |
CN102652819A (zh) * | 2012-03-06 | 2012-09-05 | 深圳市国源药业有限公司 | 一种妇炎康分散片及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105311325A (zh) * | 2015-10-27 | 2016-02-10 | 李成艳 | 一种治疗子宫肌瘤的组合物栓剂及其制备方法 |
CN106177797A (zh) * | 2016-08-30 | 2016-12-07 | 佛山市弘泰药物研发有限公司 | 一种妇科炎症的中成药及其制备工艺 |
CN111265602A (zh) * | 2020-03-31 | 2020-06-12 | 江西普正制药股份有限公司 | 血平制剂在制备治疗子宫肌瘤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103157062B (zh) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103007234B (zh) | 一种治疗子宫内膜异位引起痛经的中药制剂及其制备方法 | |
CN102342992B (zh) | 一种用于治疗失眠的中药组合物及其制剂的制备方法 | |
CN103041208B (zh) | 一种治疗妇女更年期综合征的中药制剂及其制备方法 | |
CN102836409B (zh) | 用于治疗产后恶露不绝的中药及制备方法 | |
CN102526566B (zh) | 一种治疗子宫肌瘤和卵巢囊肿的中药制剂及制备方法 | |
CN104474500A (zh) | 一种补血调经的中药保健品及其制备方法 | |
CN104353019A (zh) | 舒经调脏的中药热敷袋及其制备方法 | |
CN101869688B (zh) | 一种治疗子宫肌瘤的中药复方制剂 | |
CN103157062B (zh) | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 | |
CN103330837B (zh) | 一种治疗绝经妇女骨质疏松症的中药组合物 | |
CN105031331A (zh) | 一种治疗痛经的肚脐贴剂及其制备方法 | |
CN104324330A (zh) | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN105770691A (zh) | 一种用于治疗宫颈癌的药物制剂及其用途 | |
CN104800553A (zh) | 一种治疗更年期失眠症的中药组合物及其制备方法 | |
CN104800675A (zh) | 用于治疗活动期溃疡性结肠炎的药物 | |
CN104069305A (zh) | 一种治疗慢性盆腔炎的中药组合物及其制备方法 | |
CN104189615B (zh) | 一种治疗崩漏的中药制剂及其制备方法 | |
CN102716341B (zh) | 治疗急性消化性溃疡出血的中药组合物及其制备方法 | |
CN105983020A (zh) | 一种治疗炎性外痔的药物组合物及其应用 | |
CN105998579A (zh) | 一种治疗输卵管炎性不孕症的药物及其制备方法和应用 | |
CN105521370A (zh) | 一种用于治疗结肠癌的药物制剂及其用途 | |
CN101249249A (zh) | 一种治疗子宫肌瘤、子宫、输卵管、卵巢囊肿的药物及制备方法 | |
CN105687666A (zh) | 一种治疗慢性痛风性关节炎的中药组合物及其制备方法 | |
CN105250634A (zh) | 一种用于治疗产后便秘的中药组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN GUOYUAN CHINESE MEDICINE CO., LTD. Free format text: FORMER NAME: SHENZHEN GUOYUAN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 518112, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee after: SHENZHEN GUOYUAN MEDICINES Co.,Ltd. Address before: 518112, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee before: Shenzhen Guoyuan Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190920 Address after: 528449 Guangdong province Zhongshan Nanlang town of Southern China City, modern Chinese medicine Kang Street No. 12 Patentee after: GUANGDONG GUOYUAN GUOYAO PHARMACEUTICAL Co.,Ltd. Address before: 518112, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee before: SHENZHEN GUOYUAN MEDICINES Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 528449 12 Southern China modern Chinese medicine city, Nan Lang Town, Zhongshan, Guangdong. Patentee after: Guoyuan Guoyao (Guangdong) Pharmaceutical Group Co.,Ltd. Address before: 528449 12 Southern China modern Chinese medicine city, Nan Lang Town, Zhongshan, Guangdong. Patentee before: GUANGDONG GUOYUAN GUOYAO PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating gynecological lumpy diseases such as uterine fibroids, its preparation method, and application Effective date of registration: 20230314 Granted publication date: 20150318 Pledgee: Science and Technology Branch of Torch Development Zone of Zhongshan Rural Commercial Bank Co.,Ltd. Pledgor: Guoyuan Guoyao (Guangdong) Pharmaceutical Group Co.,Ltd. Registration number: Y2023980034725 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |